Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
Colletti SL, Frie JL, Dixon EC, Singh SB, Choi BK, Scapin G, Fitzgerald CE, Kumar S, Nichols EA, O'Keefe SJ, O'Neill EA, Porter G, Samuel K, Schmatz DM, Schwartz CD, Shoop WL, Thompson CM, Thompson JE, Wang R, Woods A, Zaller DM, Doherty JB.
Colletti SL, et al. Among authors: thompson je, thompson cm.
J Med Chem. 2003 Jan 30;46(3):349-52. doi: 10.1021/jm025585h.
J Med Chem. 2003.
PMID: 12540232